Drugs.com - New Drug Approvals

FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)

South San Francisco, CA -- February 12, 2025 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi&reg...

Feb 13, 2025 - 04:24
 0
FDA Approves Genentech’s Evrysdi Tablet as First and Only Tablet for Spinal Muscular Atrophy (SMA)
South San Francisco, CA -- February 12, 2025 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi®...
Read More

Tags:

Previous Article

Palvella Therapeutics to Expand Phase 3 SELVA Clinical Trial of Qtorin 3.9% Rapa...

Next Article

New EV Charging Station Schemes Thwart Trump’s NEVI Squeeze

Related Posts

FDA Approves Vtama (tapinarof) Cream for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

FDA Approves Vtama (tapinarof) Cream for the Treatment ...

Feb 9, 2025  0

FDA Approves Romvimza (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor

FDA Approves Romvimza (vimseltinib) for the Treatment o...

Feb 17, 2025  0

FDA Approves Unloxcyt (cosibelimab-ipdl) for the Treatment of Cutaneous Squamous Cell Carcinoma

FDA Approves Unloxcyt (cosibelimab-ipdl) for the Treatm...

Feb 9, 2025  0